CRISPR Therapeutics AG $CRSP Shares Acquired by EagleClaw Capital Managment LLC

EagleClaw Capital Managment LLC raised its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 77.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 30,220 shares of the company’s stock after buying an additional 13,170 shares during the period. EagleClaw Capital Managment LLC’s holdings in CRISPR Therapeutics were worth $1,672,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Moors & Cabot Inc. grew its position in shares of CRISPR Therapeutics by 9.5% in the third quarter. Moors & Cabot Inc. now owns 7,373 shares of the company’s stock valued at $408,000 after purchasing an additional 641 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in CRISPR Therapeutics by 178.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 212,645 shares of the company’s stock worth $11,764,000 after purchasing an additional 136,379 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in CRISPR Therapeutics by 2.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 24,136 shares of the company’s stock worth $1,338,000 after purchasing an additional 658 shares during the last quarter. Privium Fund Management B.V. lifted its holdings in CRISPR Therapeutics by 8.9% during the 3rd quarter. Privium Fund Management B.V. now owns 48,974 shares of the company’s stock worth $2,709,000 after purchasing an additional 4,000 shares during the last quarter. Finally, Pekin Hardy Strauss Inc. acquired a new stake in CRISPR Therapeutics during the 3rd quarter worth approximately $1,481,000. 69.20% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on CRSP shares. Wall Street Zen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. UBS Group began coverage on CRISPR Therapeutics in a report on Thursday, October 15th. They issued a “neutral” rating and a $52.00 price objective for the company. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $55.00 price objective on shares of CRISPR Therapeutics in a report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Thursday, October 15th. Finally, Piper Sandler reissued an “overweight” rating and set a $110.00 target price on shares of CRISPR Therapeutics in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $72.93.

CRISPR Therapeutics Stock Down 0.9%

CRSP stock opened at $42.24 on Friday. The company’s 50-day moving average price is $52.09 and its two-hundred day moving average price is $52.54. The company has a debt-to-equity ratio of 0.36, a current ratio of 16.21 and a quick ratio of 16.21. CRISPR Therapeutics AG has a 12 month low of $41.75 and a 12 month high of $63.45.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, November 2nd. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.06) by ($0.09). CRISPR Therapeutics had a negative return on equity of 25.59% and a negative net margin of 1,812.07%. The company had revenue of $12.67 million for the quarter, compared to analyst estimates of $14.75 million. The company’s revenue was up 1311.1% compared to the same quarter last year. On average, analysts predict that CRISPR Therapeutics AG will post -4.54 EPS for the current year.

Insiders Place Their Bets

In related news, General Counsel James Kasinger sold 1,040 shares of the company’s stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $49.26, for a total value of $51,230.40. Following the sale, the general counsel owned 95,857 shares in the company, valued at $4,721,915.82. This represents a 1.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ali Behbahani sold 13,679 shares of the stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $57.09, for a total value of $780,934.11. Following the completion of the sale, the director directly owned 16,637 shares of the company’s stock, valued at $949,806.33. The trade was a 45.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 93,558 shares of company stock valued at $4,881,663. Company insiders own 5.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval.